Harmony Biosciences has outlined a net revenue target of $1 billion to $1.04 billion [1] for the 2026 fiscal year.
This financial goal and the development of new drug formulations are central to the company's strategy to maintain profitability and secure its market position through the next decade.
Company executives Jeffrey Dayno, President, CEO and Director, and Kumar Budur, Executive Vice President and Chief Medical and Scientific Officer, provided updates on the pitolisant GR program. The company said the program is on track for a New Drug Application (NDA) submission in the second quarter of 2026 [2]. Following that submission, Harmony is targeting a Prescription Drug User Fee Act (PDUFA) date in the first quarter of 2027 [2].
Dayno said, "We are a profitable, self-funding biotech company that continues to operate from a position of strength."
Budur said the company remains on track for the NDA submission in the second quarter of 2026 and the target PDUFA date in the first quarter of 2027 [2].
According to the company, these milestones are designed to protect the pitolisant franchise into the 2030s. By extending the lifecycle of its primary product line, Harmony aims to ensure it remains a self-funding entity, while expanding its clinical reach.
“"We are a profitable, self-funding biotech company that continues to operate from a position of strength."”
The aggressive revenue target and the push for a new formulation of pitolisant indicate a strategy to prevent a 'patent cliff.' By securing a PDUFA date in early 2027, Harmony seeks to maintain exclusivity and commercial dominance over its franchise, ensuring long-term financial stability without relying on external venture capital.
